title: The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis.
abstract: BACKGROUND
  There have been inconsistent results from case-control studies assessing the association of the PON1 Q192R polymorphism with coronary heart disease (CHD). Most studies have included predominantly men and the association in women is unclear. Since lipid levels vary between the sexes the antioxidant effect of PON1 and any genes associated with it may also vary by sex. We have examined the association of the PON1 Q192R polymorphism with CHD in a large cohort of British women and combined the results from our cohort study with those from all other published studies.
  
  
  RESULTS
  The distribution of genotypes was the same among women with CHD and those without disease. The odds ratio (95% confidence interval) of having CHD comparing those with either the QR or RR genotype to those with QQ genotype (dominant model of association) was 1.03 (0.89, 1.21) and the per allele odds ratio was 0.98 (0.95, 1.01). In a meta-analysis of this and 38 other published studies (10,738 cases and 17,068 controls) the pooled odds ratio for the dominant effect was 1.14 (1.08, 1.20) and for the per allele effect was 1.10 (1.06, 1.13). There was evidence of small study bias in the meta-analyses and the dominant effect among those studies with 500 or more cases was 1.05 (0.96, 1.15). Ethnicity and reporting of whether the genotyping was done blind to the participants clinical status also contributed to heterogeneity between studies, but there was no difference in effect between studies with 50% or more women compared to those with fewer women and no difference between studies of healthy populations compared to those at high risk (with diabetes, renal disease of familial hypercholesterolaemia).
  
  
  CONCLUSIONS
  There is no robust evidence that the PON1 Q192R polymorphism is associated with CHD risk in Caucasian women or men.
authors.affiliation: Department of Social Medicine, University of Bristol, UK. d.a.lawlor@bristol.ac.uk
authors.forename: Debbie A
authors.initials: DA
authors.lastname: Lawlor
authors.forename: Ian N M
authors.initials: IN
authors.lastname: Day
authors.forename: Tom R
authors.initials: TR
authors.lastname: Gaunt
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Hinks
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Briggs
authors.forename: Matthew
authors.initials: M
authors.lastname: Kiessling
authors.forename: Nick
authors.initials: N
authors.lastname: Timpson
authors.forename: George Davey
authors.initials: GD
authors.lastname: Smith
authors.forename: Shah
authors.initials: S
authors.lastname: Ebrahim
mesh_terms: D000368:Aged; D001120:Arginine / Q000235:genetics*; D043303:Aryldialkylphosphatase / Q000235:genetics*; D015331:Cohort Studies; D003327:Coronary Disease / Q000235:genetics*; D005260:Female; D005973:Glutamine / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D005973:Glutamine; D001120:Arginine; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human